Maxim Group reiterated their buy rating on shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) in a report issued on Thursday morning. Maxim Group currently has a $6.00 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also issued reports on the stock. HC Wainwright started coverage on shares of Onconova Therapeutics in a research report on Monday, October 9th. They set a buy rating and a $6.00 target price on the stock. Dawson James reaffirmed a buy rating on shares of Onconova Therapeutics in a research report on Tuesday, July 25th. Finally, ValuEngine raised shares of Onconova Therapeutics from a strong sell rating to a sell rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $7.33.
Onconova Therapeutics (NASDAQ:ONTX) remained flat at $$1.95 during trading hours on Thursday. 17,446 shares of the company traded hands, compared to its average volume of 399,183. Onconova Therapeutics has a 1 year low of $1.46 and a 1 year high of $3.88.
Onconova Therapeutics (NASDAQ:ONTX) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.43. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. equities analysts anticipate that Onconova Therapeutics will post -3.03 earnings per share for the current fiscal year.
WARNING: “Onconova Therapeutics, Inc. (ONTX) Given “Buy” Rating at Maxim Group” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/11/05/onconova-therapeutics-inc-ontx-given-buy-rating-at-maxim-group.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Onconova Therapeutics by 58.4% during the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 32,418 shares in the last quarter. Sabby Management LLC boosted its stake in Onconova Therapeutics by 104.0% during the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after buying an additional 399,640 shares in the last quarter. Finally, Tyndall Capital Partners L P boosted its stake in Onconova Therapeutics by 91.4% during the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock worth $2,154,000 after buying an additional 476,190 shares in the last quarter. Hedge funds and other institutional investors own 26.81% of the company’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
What are top analysts saying about Onconova Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Onconova Therapeutics Inc. and related companies.